JP2008508858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508858A5 JP2008508858A5 JP2007513435A JP2007513435A JP2008508858A5 JP 2008508858 A5 JP2008508858 A5 JP 2008508858A5 JP 2007513435 A JP2007513435 A JP 2007513435A JP 2007513435 A JP2007513435 A JP 2007513435A JP 2008508858 A5 JP2008508858 A5 JP 2008508858A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pharmaceutical composition
- fragment
- antibody comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 27
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 20
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims 17
- 210000004881 tumor cell Anatomy 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000004412 neuroendocrine cell Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57164804P | 2004-05-13 | 2004-05-13 | |
| PCT/US2005/016920 WO2005120557A2 (en) | 2004-05-13 | 2005-05-13 | Inhibition of macrophage-stimulating protein receptor (ron) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508858A JP2008508858A (ja) | 2008-03-27 |
| JP2008508858A5 true JP2008508858A5 (enExample) | 2008-07-03 |
Family
ID=35503660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513435A Pending JP2008508858A (ja) | 2004-05-13 | 2005-05-13 | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090246205A1 (enExample) |
| EP (1) | EP1773881A4 (enExample) |
| JP (1) | JP2008508858A (enExample) |
| CA (1) | CA2566647A1 (enExample) |
| WO (1) | WO2005120557A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008029807A1 (fr) * | 2006-09-06 | 2008-03-13 | Japan Science And Technology Agency | Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide |
| WO2008156865A2 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| AR069393A1 (es) | 2007-11-21 | 2010-01-20 | Imclone Systems Inc | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo |
| WO2009080753A1 (en) * | 2007-12-21 | 2009-07-02 | Patrys Limited | Pm-2 antibodies and methods for treating metastasis |
| JP2011509687A (ja) * | 2008-01-22 | 2011-03-31 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｒｏｎ抗体およびその使用 |
| AU2009241589B2 (en) | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2010014751A2 (en) * | 2008-07-29 | 2010-02-04 | Texas Tech University | Monoclonal antibody zt/2f2 in targeted therapy of cancers overexpressing the ron receptor tyrosine kinase |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| SG175427A1 (en) * | 2009-05-01 | 2011-12-29 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2011090762A1 (en) * | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Heterodimer binding proteins and uses thereof |
| AU2011276285A1 (en) | 2010-07-06 | 2013-01-24 | Aveo Pharmaceuticals, Inc. | Anti-RON antibodies |
| AR082461A1 (es) | 2010-08-03 | 2012-12-12 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2013002270A (es) | 2010-08-26 | 2013-05-14 | Abbvie Inc | Inmonoglubinas de dominio variable doble y usos de las mismas. |
| UY34558A (es) | 2011-12-30 | 2013-07-31 | Abbvie Inc | Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17 |
| WO2013173745A1 (en) * | 2012-05-18 | 2013-11-21 | Galaxy Biotech, Llc | Monoclonal antibodies to macrophage stimulating protein |
| CA2890263C (en) | 2012-11-01 | 2020-03-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| EP3037434B1 (en) * | 2013-08-20 | 2018-07-18 | Japan Science and Technology Agency | Human antibody kappa type light chain complex-containing composition and method for producing same |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2018052789A1 (en) | 2016-09-08 | 2018-03-22 | Pcm Targetech, Llc | Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy |
| US11376307B2 (en) * | 2018-01-08 | 2022-07-05 | Susavion Biosciences, Inc. | Compositions and methods of treating cancer with glycomimetic peptides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US5861301A (en) * | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| EP1299419A2 (en) * | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| AU2002258798A1 (en) * | 2001-04-13 | 2002-10-28 | Children's Hospital Medical Center | Methods for the treatment of hepatic disorders |
| EP1423428B2 (en) * | 2001-06-20 | 2012-11-14 | Fibron Ltd. | Antibodies that block fgfr3 activation, methods of screening for and uses thereof |
| EP1485075A4 (en) * | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| US20040101920A1 (en) * | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US20040185506A1 (en) * | 2003-03-21 | 2004-09-23 | Heavner George A. | Epitope mapping using nuclear magnetic resonance |
-
2005
- 2005-05-13 US US11/596,030 patent/US20090246205A1/en not_active Abandoned
- 2005-05-13 JP JP2007513435A patent/JP2008508858A/ja active Pending
- 2005-05-13 CA CA002566647A patent/CA2566647A1/en not_active Abandoned
- 2005-05-13 WO PCT/US2005/016920 patent/WO2005120557A2/en not_active Ceased
- 2005-05-13 EP EP05782440A patent/EP1773881A4/en not_active Withdrawn